vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and TRIMAS CORP (TRS). Click either name above to swap in a different company.
TRIMAS CORP is the larger business by last-quarter revenue ($256.5M vs $191.2M, roughly 1.3× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 3.8%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 3.3%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Trimas Corp is a diversified industrial manufacturing enterprise that designs, produces and distributes a wide portfolio of engineered products, including specialized fasteners, aerospace components, custom packaging solutions, and consumer & industrial hardware. It primarily serves aerospace, automotive, construction, consumer goods and industrial sectors, with core operations across North America and selected global markets.
AXSM vs TRS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $256.5M |
| Net Profit | — | $81.7M |
| Gross Margin | — | 12.8% |
| Operating Margin | -33.1% | 5.7% |
| Net Margin | — | 31.9% |
| Revenue YoY | 57.4% | 3.8% |
| Net Profit YoY | — | 236.9% |
| EPS (diluted) | — | $2.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $256.5M | ||
| Q4 25 | $196.0M | $-140.0M | ||
| Q3 25 | $171.0M | $269.3M | ||
| Q2 25 | $150.0M | $274.8M | ||
| Q1 25 | $121.5M | $241.7M | ||
| Q4 24 | $118.8M | $-66.2M | ||
| Q3 24 | $104.8M | $229.4M | ||
| Q2 24 | $87.2M | $240.5M |
| Q1 26 | — | $81.7M | ||
| Q4 25 | $-28.6M | $81.7M | ||
| Q3 25 | $-47.2M | $9.3M | ||
| Q2 25 | $-48.0M | $16.7M | ||
| Q1 25 | $-59.4M | $12.4M | ||
| Q4 24 | $-74.9M | $5.6M | ||
| Q3 24 | $-64.6M | $2.5M | ||
| Q2 24 | $-79.3M | $10.9M |
| Q1 26 | — | 12.8% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 12.8% | ||
| Q2 25 | — | 13.8% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 15.4% | ||
| Q2 24 | — | 14.4% |
| Q1 26 | -33.1% | 5.7% | ||
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | 6.2% | ||
| Q2 25 | -24.5% | 9.9% | ||
| Q1 25 | -46.9% | 9.0% | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | 3.6% | ||
| Q2 24 | -89.5% | 7.4% |
| Q1 26 | — | 31.9% | ||
| Q4 25 | -14.6% | -58.4% | ||
| Q3 25 | -27.6% | 3.5% | ||
| Q2 25 | -32.0% | 6.1% | ||
| Q1 25 | -48.9% | 5.1% | ||
| Q4 24 | -63.1% | -8.5% | ||
| Q3 24 | -61.7% | 1.1% | ||
| Q2 24 | -91.0% | 4.5% |
| Q1 26 | — | $2.03 | ||
| Q4 25 | $-0.55 | $2.01 | ||
| Q3 25 | $-0.94 | $0.23 | ||
| Q2 25 | $-0.97 | $0.41 | ||
| Q1 25 | $-1.22 | $0.30 | ||
| Q4 24 | $-1.54 | $0.14 | ||
| Q3 24 | $-1.34 | $0.06 | ||
| Q2 24 | $-1.67 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $30.0M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $705.6M |
| Total Assets | $713.6M | $1.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | $30.0M | ||
| Q4 25 | $322.9M | $30.0M | ||
| Q3 25 | $325.3M | $33.6M | ||
| Q2 25 | $303.0M | $30.3M | ||
| Q1 25 | $300.9M | $32.7M | ||
| Q4 24 | $315.4M | $23.1M | ||
| Q3 24 | $327.3M | $26.9M | ||
| Q2 24 | $315.7M | $35.0M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $469.2M | ||
| Q3 25 | — | $407.1M | ||
| Q2 25 | — | $424.5M | ||
| Q1 25 | — | $434.2M | ||
| Q4 24 | — | $398.1M | ||
| Q3 24 | — | $409.9M | ||
| Q2 24 | — | $427.4M |
| Q1 26 | — | $705.6M | ||
| Q4 25 | $88.3M | $705.6M | ||
| Q3 25 | $73.7M | $725.0M | ||
| Q2 25 | $73.1M | $715.3M | ||
| Q1 25 | $53.2M | $686.6M | ||
| Q4 24 | $57.0M | $667.3M | ||
| Q3 24 | $92.9M | $682.8M | ||
| Q2 24 | $102.9M | $675.9M |
| Q1 26 | $713.6M | $1.5B | ||
| Q4 25 | $689.8M | $1.5B | ||
| Q3 25 | $669.3M | $1.4B | ||
| Q2 25 | $639.8M | $1.4B | ||
| Q1 25 | $596.7M | $1.4B | ||
| Q4 24 | $568.5M | $1.3B | ||
| Q3 24 | $561.5M | $1.4B | ||
| Q2 24 | $548.2M | $1.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | 0.59× | ||
| Q1 25 | — | 0.63× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.60× | ||
| Q2 24 | — | 0.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $117.5M |
| Free Cash FlowOCF − Capex | — | $36.8M |
| FCF MarginFCF / Revenue | — | 14.4% |
| Capex IntensityCapex / Revenue | — | 18.9% |
| Cash ConversionOCF / Net Profit | — | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | — | $109.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $117.5M | ||
| Q4 25 | $-18.7M | $41.5M | ||
| Q3 25 | $1.0M | $36.5M | ||
| Q2 25 | $-32.4M | $30.3M | ||
| Q1 25 | $-43.4M | $9.2M | ||
| Q4 24 | $-26.2M | $27.1M | ||
| Q3 24 | $-18.6M | $22.0M | ||
| Q2 24 | $-30.1M | $18.4M |
| Q1 26 | — | $36.8M | ||
| Q4 25 | $-18.7M | $36.8M | ||
| Q3 25 | $988.0K | $22.8M | ||
| Q2 25 | $-32.4M | $13.2M | ||
| Q1 25 | $-43.7M | $-3.8M | ||
| Q4 24 | $-26.2M | $12.1M | ||
| Q3 24 | $-18.7M | $10.2M | ||
| Q2 24 | $-30.2M | $7.5M |
| Q1 26 | — | 14.4% | ||
| Q4 25 | -9.6% | -26.3% | ||
| Q3 25 | 0.6% | 8.5% | ||
| Q2 25 | -21.6% | 4.8% | ||
| Q1 25 | -36.0% | -1.6% | ||
| Q4 24 | -22.1% | -18.3% | ||
| Q3 24 | -17.9% | 4.4% | ||
| Q2 24 | -34.6% | 3.1% |
| Q1 26 | — | 18.9% | ||
| Q4 25 | 0.0% | -3.4% | ||
| Q3 25 | 0.0% | 5.1% | ||
| Q2 25 | 0.0% | 6.2% | ||
| Q1 25 | 0.3% | 5.4% | ||
| Q4 24 | 0.0% | -22.6% | ||
| Q3 24 | 0.1% | 5.2% | ||
| Q2 24 | 0.1% | 4.5% |
| Q1 26 | — | 1.44× | ||
| Q4 25 | — | 0.51× | ||
| Q3 25 | — | 3.92× | ||
| Q2 25 | — | 1.81× | ||
| Q1 25 | — | 0.74× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 8.71× | ||
| Q2 24 | — | 1.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
TRS
Segment breakdown not available.
